When we stratified the samples by grade, the loss of MTAP expression in the high-grade glioma subgroup was almost two-fold greater (46.6%, 228/489) than in the low-grade glioma subgroup (27.8%; 5/18) (Table 2 and Figure 3E). Here, MTAP is linked to central nervous system cancer.